YCBD· Health Care› Drug Manufacturers - Specialty & Generic

cbdMD, Inc.

Stage 4 · Declining · week 17

As of Oct 22, 2026, cbdMD is in Stage 4, the downtrend phase, now in week 17 (since Jun 26, 2026). It closed at $0.37, 83.6% below its 52-week high and below its 200-day average, which is falling.

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. More about the company

$0.37

-3.42% today

$4.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is YCBD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S4 34w

S4 30w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 23w → S1 7w → S4 4w → S1 8w → S4 34w → S1 6w → S4 30w → S1 7w → S4 4w → S1 5w → S2 4w → S3 1w → S4 9w → S1 6w → S4 17w current

Total tracked: 165 weeks across 15 stage runs.

YCBD among Drug Manufacturers - Specialty & Generic66th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…66	YCBDcbdMD, Inc.	Stage 4 · wk 17	17	−18.4%

vs 52W High

-83.6%

$0.35 lo$2.27 hi

83.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 17

1w13w26w

Week 17, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-45.7%

200 DMA: $0.69 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.16x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.4%

-30.7%

-63.1%

YTD

-67.8%

-64.8%

Scan Membership

Breakout Watch

Latest: 2020-11-30

5 appearances in last 60 days. First seen: 2018-11-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 17 · Vol 0.16x

2026-10-21S4

Wk 17 · Vol 0.16x

2026-10-20S4

Wk 17 · Vol 0.16x

2026-10-19S4

Wk 16 · Vol 0.08x

2026-10-16S4

Wk 16 · Vol 0.14x

2026-10-15S4

Wk 16 · Vol 0.15x

2026-10-14S4

Wk 16 · Vol 0.23x

2026-10-13S4

Wk 16 · Vol 0.42x

2026-10-12S4

Wk 15 · Vol 0.53x

2026-10-09S4

Wk 15 · Vol 0.09x

2026-10-08S4

Wk 15 · Vol 0.15x

2026-10-07S4

Wk 15 · Vol 0.16x

Moving averages & range

50 DMA

$0.45

200 DMA

$0.69

52W High

$2.27

52W Low

$0.35

5D Low

$0.35

Resistance levels (recent highs)

20d High

$0.47

60d High

$0.60

120d High

$0.91

250d High

$2.27

Next resistance

+25.7%

to 20d High

P/E (TTM)

1.6

Forward -0.4

ROE

-40.3%

Profit margin -13.8%

Dividend Yield

0.00%

P/B 0.5

cbdMD: quick answers

What stage is cbdMD in?

As of Oct 22, 2026, cbdMD (YCBD) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 26, 2026 and is in week 17. What the four stages mean

Is cbdMD in an uptrend?

No. cbdMD is in a Stage 4 downtrend. It trades 45.7% below its 200-day average, which is falling.

How far is cbdMD from its 52-week high?

cbdMD closed at $0.37 on Oct 22, 2026, 83.6% below its 52-week high of $2.27. Its 52-week low is $0.35.

How has cbdMD performed over the past year?

As of Oct 22, 2026, cbdMD is down 64.8% over the past year and down 67.8% so far in 2026.

Which sector and industry is cbdMD in?

cbdMD is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.